Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.27, no.1, pp.40-45, 2021 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 27 Issue: 1
- Publication Date: 2021
- Doi Number: 10.1177/1078155220909426
- Journal Name: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
- Page Numbers: pp.40-45
- Keywords: late adjuvant therapy, melanoma, survival, Temozolomide
- Istanbul University Affiliated: Yes